Rome, 10 Nov. (Adnkronos Health) – “Over these 21 years, we have learned that discussing the healthcare system and the health system means discussing the security, sovereignty, and future of Italian and European citizens. There are two major scenarios that are disrupting the health ecosystem in our country: one is the MFN (Most Favored Nation) policy of the Trump administration, which completely revolutionizes the rules of the game concerning research and manufacturing production in Europe, to the advantage of the United States; the second is the Chinese policy, now decades old, aimed at conquering the world in life sciences.” So said Valerio De Molli, Managing Partner and CEO of The European House – Ambrosetti and Teha Group, speaking in Rome, at Spazio Esposizioni, at the XXI edition of the Meridiano Sanità Forum, titled ‘Healthcare and life sciences: governing transitions, building the future’, the healthcare think tank of The European House – Ambrosetti.
“By now, one in two new innovations originates in China, with significant predominance,” continues De Molli. “In parallel, a major silent revolution is taking place in our country, destined to characterize the scenario for the next thirty years: the demographic and population structure is profoundly changing. In 2050, in fact, we will have two people over seventy-five for every 10 citizens, and this is relevant because the per capita cost for someone over seventy-five is 8 times higher than that of a twenty-year-old. This leads to a compression and an increase in healthcare spending, which will rise from the current 140 billion to over 220 billion in 2050. We must make all of this sustainable through adequate policy guidelines and redesign the priorities for the sector.”
“Regarding the main critical issues of the Italian healthcare system, there is an overall undersizing of the number of specialized doctors and nurses,” explains De Molli. “One in two general practitioners exceeds the maximum number of patients they can have, and the number of nurses is largely insufficient for the necessary staffing in a country where the demand for healthcare and health has grown exponentially. We also have an undersizing and undervaluation of these professions, which are paid two and a half times less than in the best countries in Europe, half compared to Germans, and almost half compared to French. So, on one hand, there is a structural issue, and on the other, there is the need to restore centrality to manufacturing companies and research. Our Meridiano Sanità partners are the 6 companies that account for 20% of all global research and 20% of all global innovation. They are all surprised by the lack of attention that research and manufacturing are receiving in our country and also in Europe,” concludes De Molli.